UK markets closed

Valneva SE (VALN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
67.28+7.68 (+12.89%)
At close: 04:00PM EST
69.00 +1.72 (+2.56%)
After hours: 05:39PM EST
Full screen
Trade prices are not sourced from all markets
Previous close59.60
Open64.77
Bid63.80 x 1000
Ask75.00 x 800
Day's range63.00 - 67.65
52-week range24.16 - 67.65
Volume134,817
Avg. volume126,426
Market cap3.53B
Beta (5Y monthly)0.95
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    Valneva and IDT Biologika Announce Collaboration for Production of Inactivated COVID-19 Vaccine VLA2001

    Saint-Herblain (France) and Dessau-Roßlau (Germany), November 29, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and IDT Biologika today announced their collaboration for the production of Valneva’s inactivated COVID-19 vaccine candidate VLA2001. This follows last week’s announcement that Valneva signed an Advance Purchase Agreement with the European Commission to supply up to 60 million doses of VLA2001, over two years. Under the collaboration, IDT Biologika

  • Globe Newswire

    Valneva Signs Purchase Agreement with European Commission for its Inactivated COVID-19 Vaccine VLA2001

    Saint-Herblain (France), November 23, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has signed an Advance Purchase Agreement (APA) with the European Commission (EC) to supply up to 60 million doses of its inactivated COVID-19 vaccine candidate, VLA2001, over two years. The agreement follows the announcement made earlier this month that the EC had approved the APA1. Under the terms of the agreement following final review of the volumes

  • Globe Newswire

    Valneva Reports Nine-Month 2021 Revenue and Cash

    Strong financial position Cash and cash equivalents of €247.9 million at the end of September 2021 Reflects $107.6 million of gross proceeds raised in a US IPO and placement in Europe in the second quarter of 2021Does not include $102.0 million of gross proceeds raised in a follow-on offering in the US and Europe in the fourth quarter of 2021 Total revenue (excluding COVID) of €69.8 million in the first nine months of 2021 compared to €58.8 million in the first nine months of 2020 Product sales